Myanmar

in page functions
[French]
Myanmar
Total population (2017) 54,836,254
Birth cohort (2017) 937,697
Surviving Infants (surviving to 1 year per year, 2017) 897,244
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 40/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 50/1000
World Bank Index, IDA (2015) 3.08
Gross Nation Income (per capita US$, 2015) 1,160
Co-financing group (2017) Preparatory transition
No. of districts/territories (2016) 330

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Myanmar

Type of support

Approvals

2001-2021 (US$)
(18 Oct 2017)

Commitments

2001-2021 (US$)
(18 Oct 2017)

Disbursements

2000-2017 (US$)
(18 Oct 2017)

% Disbursed

(18 Oct 2017)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Total $187,923,346 $274,694,346 $157,531,451
Health system strengthening (HSS 1) $32,770,639 $32,770,639 $29,773,024 91%
Health system strengthening (HSS 2) $20,000,000 $52,000,000
HepB mono (NVS) $13,833,610 $13,833,610 $13,833,610 100%
Immunisation services support (ISS) $7,707,080 $7,707,080 $7,707,080 100%
Injection Safety Devices (NVS) $1,293,000 $2,402,500 $1,558,112 121%
Injection safety support (INS) $2,083,978 $2,083,978 $2,083,978 100%
IPV (NVS) $3,295,890 $3,295,890 $2,514,210 76%
JEV (NVS) $6,546,000 $6,546,000 $7,094,530 108%
JEV - Operational costs (OPC) $9,125,500 $9,125,500 $9,125,500 100%
JEV-Routine (NVS) $545,000 $545,000
Measles (NVS) $3,031,678 $3,031,678 $3,189,530 105%
Measles-Rubella (NVS) $10,808,711 $10,808,711 $10,808,711 100%
MR - Operational costs (OPC) $11,357,500 $11,357,500 $11,357,500 100%
Penta (NVS) $35,196,760 $51,118,260 $28,166,741 80%
Pneumo (NVS) $23,801,500 $61,541,500 $23,792,425 100%
Vaccine Introduction Grant (VIG) $6,526,500 $6,526,500 $6,526,500 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Myanmar DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2016)

Grade of confidence


N/A
DTP3 - Official country estimates (2016) 90%
M:F sex ratio at birth (2017) 1.03
Household survey: DTP3 coverage for male (2008) 97.80%
Household survey: DTP3 coverage for female (2008) 97.90%
Household survey: Last DTP3 survey (2008) 98%
% districts achieving > 80% DTP3 coverage (2016) 88%
% districts achieving < 50% DTP3 coverage (2016) 5%
MCV WHO/UNICEF estimates (2016) 91%

Breakdown of support

Non-vaccine support Vaccine support
42% 58%
$66,573,582 $90,957,869

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Myanmar

29 September 2017

Gavi item

900,000 vaccines 'en route' to Cox's Bazar to prevent cholera

Oral cholera vaccine will protect Rohingya refugees seeking shelter in Bangladesh as well as resident population.

01 July 2016

Close to 1 million Myanmar children to be protected with pneumococcal vaccine

With July’s launch of pneumococcal vaccine, which protects against the main cause of deadly pneumonia, Myanmar has introduced 9 vaccines against 10 diseases into its national immunisation programme.

20 May 2014

Reasons to invest

Reasons to invest in the GAVI Alliance

From singers and Presidents to Ministers and advocates, GAVI Alliance supporters explain why they are backing the Alliance’s vision for 2020

close icon

modal window here